cystinyl-aspartyl-prolyl-glycyl-tyrosyl-isoleucyl-glycyl-seryl-arginyl-nh2 has been researched along with Angiogenesis, Pathologic in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Iwahana, M; Osada, Y; Sakamoto, N; Tanaka, NG | 1 |
1 other study(ies) available for cystinyl-aspartyl-prolyl-glycyl-tyrosyl-isoleucyl-glycyl-seryl-arginyl-nh2 and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Inhibition of angiogenesis and tumor growth by a synthetic laminin peptide, CDPGYIGSR-NH2.
Topics: Animals; Carcinoma; Cell Movement; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred ICR; Neovascularization, Pathologic; Oligopeptides; Sarcoma 180 | 1991 |